Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
CAMBRIDGE, Mass., Feb. 27, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today announced that management will present at the following upcoming investor conferences.
- Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 12:00 p.m. ET. The fireside chat will be held at the Boston Marriott Copley Place in Boston.
- Barclays Global Healthcare Conference on Tuesday, March 13, 2018 at 2:05 p.m. ET. The brief Company overview and subsequent fireside chat will be held at the Loews Miami Beach Hotel in Miami.
The presentations will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
